Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million
Regeneron is acquiring "substantially all" of 23andMe's assets for $256 million following a bankruptcy auction.
You are not logged in so some information on this page has been withheld. To see more, please log in.